期刊
MOLECULAR AND CELLULAR BIOLOGY
卷 36, 期 16, 页码 2168-2181出版社
AMER SOC MICROBIOLOGY
DOI: 10.1128/MCB.00170-16
关键词
-
资金
- Agence Nationale de la Recherche (ANR) [ANR-06-Grb14, ANR-10-Wnt-Metaboliv, ANR-09-JCJC-0057]
- Fondation pour la Recherche Medicale (FRM) (Labellisation Equipe)
- Agence Nationale de la Recherche (ANR) [ANR-09-JCJC-0057] Funding Source: Agence Nationale de la Recherche (ANR)
A long-standing paradox in the pathophysiology of metabolic diseases is the selective insulin resistance of the liver. It is characterized by a blunted action of insulin to reduce glucose production, contributing to hyperglycemia, while de novo lipogenesis remains insulin sensitive, participating in turn to hepatic steatosis onset. The underlying molecular bases of this conundrum are not yet fully understood. Here, we established a model of selective insulin resistance in mice by silencing an inhibitor of insulin receptor catalytic activity, the growth factor receptor binding protein 14 (Grb14) in liver. Indeed, Grb14 knockdown enhanced hepatic insulin signaling but also dramatically inhibited de novo fatty acid synthesis. In the liver of obese and insulin-resistant mice, downregulation of Grb14 markedly decreased blood glucose and improved liver steatosis. Mechanistic analyses showed that upon Grb14 knockdown, the release of p62/sqstm1, a partner of Grb14, activated the transcription factor nuclear factor erythroid-2-related factor 2 (Nrf2), which in turn repressed the lipogenic nuclear liver X receptor (LXR). Our study reveals that Grb14 acts as a new signaling node that regulates lipogenesis and modulates insulin sensitivity in the liver by acting at a cross-road between the insulin receptor and the p62-Nrf2-LXR signaling pathways.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据